{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:02:16Z","timestamp":1753887736624,"version":"3.41.2"},"reference-count":13,"publisher":"Radcliffe Medical Media Ltd","license":[{"start":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T00:00:00Z","timestamp":1686096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Cardiol"],"DOI":"10.15420\/ecr.2022.62","type":"journal-article","created":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T09:56:07Z","timestamp":1686131767000},"source":"Crossref","is-referenced-by-count":3,"title":["When Should We Start Sodium\u2013Glucose Co-transporter Inhibitors in Patients with Heart Failure? The Importance of Early Intervention"],"prefix":"10.15420","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5029-1203","authenticated-orcid":false,"given":"Moritake","family":"Iguchi","sequence":"first","affiliation":[{"name":"Department of Cardiac Rehabilitation, National Hospital Organization Kyoto Medical Center, Kyoto, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8980-224X","authenticated-orcid":false,"given":"Hiromichi","family":"Wada","sequence":"additional","affiliation":[{"name":"Division of Translational Research, National Hospital Organization Kyoto Medical Center, Kyoto, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5836-972X","authenticated-orcid":false,"given":"Felipe","family":"Mart\u00ednez","sequence":"additional","affiliation":[{"name":"C\u00f3rdoba National University, C\u00f3rdoba, Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7618-4043","authenticated-orcid":false,"given":"Koji","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Division of Translational Research, National Hospital Organization Kyoto Medical Center, Kyoto, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6096","published-online":{"date-parts":[[2023,6,7]]},"reference":[{"key":"ref0","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019;381:1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303; PMID: 31535829."},{"key":"ref1","unstructured":"Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020;383:1413\u201324. https:\/\/doi.org\/10.1056\/NEJMoa2022190; PMID: 32865377."},{"key":"ref2","unstructured":"McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599\u2013726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368; PMID: 34447992."},{"key":"ref3","unstructured":"Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 2021;385:1451\u201361. https:\/\/doi.org\/10.1056\/NEJMoa2107038; PMID:\u00a034449189."},{"key":"ref4","unstructured":"Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 2022;387:1089\u201398. https:\/\/doi.org\/10.1056\/NEJMoa2206286; PMID:\u00a036027570."},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Packer M, Zannad F, Anker SD. Heart failure and a preserved ejection fraction: a side-by-side examination of the PARAGON-HF and EMPEROR-Preserved trials. Circulation 2021;144:1193\u20135. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.056657; PMID:\u00a034459212.","DOI":"10.1161\/circulationaha.121.056657"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Hasegawa K, Lewis BS. Are SGLT2 inhibitors effective against \u2018all\u2019 heart failure with preserved ejection fraction? Eur Heart J Cardiovasc Pharmacother 2022;8:e10. https:\/\/doi.org\/10.1093\/ehjcvp\/pvac004; PMID:\u00a035088069.","DOI":"10.1093\/ehjcvp\/pvac004"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Vaduganathan M, Docherty KF, Claggett BL, et al. SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet 2022;400:757\u201367. https:\/\/doi.org\/10.1016\/S0140-6736(22)01429-5; PMID:\u00a036041474.","DOI":"10.1016\/s0140-6736(22)01429-5"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Vaduganathan M, Claggett BL, Jhund P, et al. Time to clinical benefit of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction: a prespecified secondary analysis of the DELIVER randomized clinical trial. JAMA Cardiol 2022;7:1259\u201363. https:\/\/doi.org\/10.1001\/jamacardio.2022.3750; PMID:\u00a036190011.","DOI":"10.1001\/jamacardio.2022.3750"},{"key":"ref9","unstructured":"Voors AA, Angermann CE, Teerlink JR, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med 2022;28:568\u201374. https:\/\/doi.org\/10.1038\/s41591-021-01659-1; PMID:\u00a035228754."},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med 2021;384:117\u201328. https:\/\/doi.org\/10.1056\/NEJMoa2030183; PMID:\u00a033200892.","DOI":"10.1056\/NEJMoa2030183"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Horiuchi Y, Matsue Y, Nogi K, et al. Early treatment with a sodium-glucose co-transporter 2 inhibitor in high-risk patients with acute heart failure: rationale for and design of the EMPA-AHF trial. Am Heart J 2023;257:85\u201392. https:\/\/doi.org\/10.1016\/j.ahj.2022.12.005; PMID:\u00a036503007.","DOI":"10.1016\/j.ahj.2022.12.005"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"McGuire DK, Shih WJ, Cosentino F, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol 2021;6:148\u201358. https:\/\/doi.org\/10.1001\/jamacardio.2020.4511; PMID:\u00a033031522.","DOI":"10.1001\/jamacardio.2020.4511"}],"container-title":["European Cardiology Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ecrjournal.com\/articleindex\/ecr.2022.62","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T09:56:18Z","timestamp":1686131778000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ecrjournal.com\/articleindex\/ecr.2022.62"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,7]]},"references-count":13,"URL":"https:\/\/doi.org\/10.15420\/ecr.2022.62","relation":{},"ISSN":["1758-3764","1758-3756"],"issn-type":[{"type":"electronic","value":"1758-3764"},{"type":"print","value":"1758-3756"}],"subject":[],"published":{"date-parts":[[2023,6,7]]},"article-number":"e41"}}